臨床整形外科54巻7号

2019年07月発行

誌上シンポジウム 骨軟部腫瘍の薬物治療アップデート

デスモイドに対する薬物治療

著者： 西田佳弘¹

所属機関： ¹名古屋大学医学部附属病院リハビリテーション科

ページ範囲：P.697 - P.702

　デスモイド型線維腫症は良悪性の中間型腫瘍であるが，局所浸潤性が強く，術後再発率がきわめて高いことから，治療方針の中心は手術から保存治療へと変わりつつある．症例によっては患者の機能を損ない，QOLを著明に低下させる．希少疾患であるため薬物治療のエビデンスに乏しく，また保険適用となっている薬剤はほとんどない．デスモイド診療に熟練した医師がmultidisciplinaryな体制で，効果の期待できる的確な薬物治療を選択することが重要である．効果の期待できる薬剤は抗がん剤と分子標的治療薬であり，以下に概説する．

参考文献

1) Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis:a series of patients surgically treated at a single institution. J Clin Oncol 2003;21(7):1390-7.

2) Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25(13):1785-91.

3) Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors:a multifactorial analysis of outcome. Cancer 1999;86(10):2045-52.

4) Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis:aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34(4):462-8.

5) Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis:a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16(9):2587-93.

6) 公益社団法人日本整形外科学会．腹腔外発生デスモイド型線維腫症診療アルゴリズムについて．https://www.joa.or.jp/public/bone/algorithm.html

7) Nishida Y, Tsukushi S, Shido Y, et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors:a pilot study. J Clin Oncol 2010;28(6):e107-9.

8) Yang S, Wang X, Jiang H, et al. Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing. Cancer Biol Ther 2017;18(10):757-60.

9) Hamada S, Urakawa H, Kozawa E, et al. Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol 2014;35(5):4561-6.

10) Fiore M, Colombo C, Radaelli S, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer 2015;51(18):2800-7.

11) Quast DR, Schneider R, Burdzik E, et al. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac:a single-center long-term observational study in 134 patients. Fam Cancer 2016;15(1):31-40.

12) Skapek SX, Anderson JR, Hill DA, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children:results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013;60(7):1108-12.

13) Goto T, Nemoto T, Ogura K, et al. Successful treatment of desmoid tumor of the chest wall with tranilast:a case report. J Med Case Rep 2010;4:384.

14) Ono H, Hori K, Tashima L, et al. A case of retroperitoneal desmoid-type fibromatosis that involved the unilateral ureter after gynaecologic surgery. Int J Surg Case Rep 2018;47:30-3.

15) Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64(6):1192-4.

16) Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children:results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007;25(5):501-6.

17) Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors:a study from the French Sarcoma Group (FSG). Ann Oncol 2012;23(1):182-6.

18) Palassini E, Frezza AM, Mariani L, et al. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J 2017;23(2):86-91.

19) Nishida Y, Tsukushi S, Urakawa H, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors:relationship to CTNNB1 mutation status. Int J Clin Oncol 2015;20(6):1211-7.

20) Constantinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatosis:effective palliation with chemotherapy. Acta Oncol 2011;50(3):455-61.

21) Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24(1):102-5.

22) Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis:results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010;16(19):4884-91.

23) Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors):an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011;22(2):452-7.

24) Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018;379(25):2417-28.

25) Szucs Z, Messiou C, Wong HH, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs 2017;28(4):421-6.

26) Agresta L, Kim H, Turpin BK, et al. Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatr Blood Cancer 2018;65(6):e26968.